Technical Analysis for XCUR - Exicure, Inc.
ADX | Long Term | Intermediate Term | Short Term |
---|---|---|---|
Strong | Down | Up | Down |
Date | Alert Name | Type | % Chg |
---|---|---|---|
Fell Below 20 DMA | Bearish | 0.00% | |
50 DMA Support | Bullish | 0.00% | |
New Uptrend | Bullish | 0.00% | |
Gapped Down | Weakness | 0.00% | |
Crossed Above 20 DMA | Bullish | -2.59% | |
Crossed Above 50 DMA | Bullish | -2.59% | |
Fell Below 50 DMA | Bearish | 4.75% | |
Spinning Top | Other | 4.75% | |
Inside Day | Range Contraction | 4.75% | |
Gapped Down | Weakness | 4.75% |
Alert | Time |
---|---|
20 DMA Resistance | about 13 hours ago |
10 DMA Resistance | about 15 hours ago |
Gap Down Closed | about 16 hours ago |
Reversed from Down | about 16 hours ago |
20 DMA Support | about 16 hours ago |
Free Daily (Stock) Chart Reading
- Earnings date: 03/25/2024
Exicure, Inc. Description
Exicure, Inc., a clinical-stage biotechnology company, develops gene regulatory and immuno-oncology therapeutics based on spherical nucleic acid (SNA) technology. Its three clinical programs include AST-008, which is in a Phase I clinical trial, an SNA consisting of toll-like receptor 9 that is designed for immuno-oncology applications; XCUR17, which is in a Phase I clinical trial, an SNA that targets the messenger RNA (mRNA) encoding interleukin 17 receptor alpha, a protein that helps in the initiation and maintenance of psoriasis; and AST-005, which is in a Phase I clinical trial, an SNA that targets TNF for the treatment of mild to moderate psoriasis. The company has collaboration agreement with Purdue Pharma L.P. Purdue Pharma for the development of AST-005; and license and development agreement DERMELIX, LLC, d/b/a Dermelix Biotherapeutics to research, develop, and commercialize Exicure's technology for the treatment of Netherton Syndrome and for five additional rare skin indications. Exicure, Inc. was founded in 2011 and is headquartered in Skokie, Illinois.
Classification
Sector: Healthcare
Industry: Biotechnology
Keywords: Biotechnology Biopharmaceutical Life Sciences Acid Psoriasis Messenger RNA Netherton Syndrome Oncology Applications
Indicator | Bull Case | Neutral / Hold | Bear Case |
---|---|---|---|
50 DMA | |||
200 DMA | |||
ADX Trend | |||
Oversold / Overbought | |||
Relative Strength |
Indicator | Value |
---|---|
52 Week High | 1.5 |
52 Week Low | 0.3647 |
Average Volume | 422,211 |
200-Day Moving Average | 0.76 |
50-Day Moving Average | 0.63 |
20-Day Moving Average | 0.65 |
10-Day Moving Average | 0.66 |
Average True Range | 0.07 |
RSI (14) | 49.49 |
ADX | 35.2 |
+DI | 19.53 |
-DI | 18.71 |
Chandelier Exit (Long, 3 ATRs) | 0.60 |
Chandelier Exit (Short, 3 ATRs) | 0.72 |
Upper Bollinger Bands | 0.74 |
Lower Bollinger Band | 0.57 |
Percent B (%b) | 0.42 |
BandWidth | 27.18 |
MACD Line | 0.01 |
MACD Signal Line | 0.02 |
MACD Histogram | -0.0066 |
Pivot Point Level | Traditional / Classic | Fibonacci | Demark | Woodie | Camarilla |
---|---|---|---|---|---|
Resistance 4 (R4) | 0.73 | ||||
Resistance 3 (R3) | 0.73 | 0.71 | 0.72 | ||
Resistance 2 (R2) | 0.71 | 0.68 | 0.71 | 0.71 | |
Resistance 1 (R1) | 0.67 | 0.67 | 0.69 | 0.67 | 0.70 |
Pivot Point | 0.65 | 0.65 | 0.66 | 0.65 | 0.65 |
Support 1 (S1) | 0.61 | 0.62 | 0.63 | 0.61 | 0.58 |
Support 2 (S2) | 0.59 | 0.61 | 0.59 | 0.57 | |
Support 3 (S3) | 0.55 | 0.59 | 0.57 | ||
Support 4 (S4) | 0.55 |